P. Kestell

858 total citations
31 papers, 690 citations indexed

About

P. Kestell is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, P. Kestell has authored 31 papers receiving a total of 690 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 16 papers in Oncology and 11 papers in Pharmacology. Recurrent topics in P. Kestell's work include Cancer therapeutics and mechanisms (13 papers), Drug Transport and Resistance Mechanisms (8 papers) and Cancer Treatment and Pharmacology (8 papers). P. Kestell is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Drug Transport and Resistance Mechanisms (8 papers) and Cancer Treatment and Pharmacology (8 papers). P. Kestell collaborates with scholars based in New Zealand, United Kingdom and Australia. P. Kestell's co-authors include Bruce C. Baguley, Baguley Bc, James W. Paxton, Zhuang Li, A. Gescher, Paul Thompson, Michael B. Jameson, Michael D. Threadgill, L‐M Ching and Malcolm D. Tingle and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

P. Kestell

31 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
P. Kestell New Zealand	16	357	255	183	146	67	31	690
Philip Kestell New Zealand	20	571 1.6×	348 1.4×	218 1.2×	155 1.1×	63 0.9×	52	1.0k
Martin C. Dyroff United States	15	418 1.2×	190 0.7×	153 0.8×	323 2.2×	40 0.6×	29	1.0k
Suoping Zhai United States	16	450 1.3×	343 1.3×	118 0.6×	77 0.5×	26 0.4×	25	969
Frank Bohnenstengel Germany	18	544 1.5×	278 1.1×	415 2.3×	67 0.5×	32 0.5×	22	1.2k
Zeen Tong United States	15	397 1.1×	139 0.5×	207 1.1×	84 0.6×	31 0.5×	35	846
Ramaswamy A. Iyer United States	17	277 0.8×	320 1.3×	190 1.0×	51 0.3×	40 0.6×	49	992
Margaret Kindlen United States	8	478 1.3×	269 1.1×	117 0.6×	53 0.4×	33 0.5×	11	842
Stefan S. De Buck United States	11	540 1.5×	361 1.4×	215 1.2×	146 1.0×	51 0.8×	13	1.0k
Hiroshi Komura Japan	17	245 0.7×	273 1.1×	286 1.6×	122 0.8×	89 1.3×	40	817
Ziqiao Yuan China	17	390 1.1×	179 0.7×	131 0.7×	84 0.6×	84 1.3×	42	854

Countries citing papers authored by P. Kestell

Since Specialization

Citations

This map shows the geographic impact of P. Kestell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Kestell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Kestell more than expected).

Fields of papers citing papers by P. Kestell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Kestell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Kestell. The network helps show where P. Kestell may publish in the future.

Co-authorship network of co-authors of P. Kestell

This figure shows the co-authorship network connecting the top 25 collaborators of P. Kestell. A scholar is included among the top collaborators of P. Kestell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Kestell. P. Kestell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kestell, P., et al.. (2008). Development and validation of a liquid chromatography–mass spectrometry (LC–MS) assay for the determination of the anti-cancer agent N-[2-(dimethylamino)ethyl]-2,6-dimethyl-1-oxo-1,2-dihydrobenzo[b]-1,6-naphthyridine-4-carboxamide (SN 28049). Journal of Chromatography B. 875(2). 368–372. 6 indexed citations

Lu, Jun, Brian D. Palmer, P. Kestell, et al.. (2003). Thalidomide metabolites in mice and patients with multiple myeloma.. PubMed. 9(5). 1680–8. 32 indexed citations

Zhou, Siwei, Yan Li, P. Kestell, & James W. Paxton. (2003). Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B. 785(1). 165–173. 20 indexed citations

Jameson, Michael B., Paul Thompson, Bruce C. Baguley, et al.. (2003). Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. British Journal of Cancer. 88(12). 1844–1850. 115 indexed citations

Kestell, P., et al.. (2003). Mechanisms by which resistant starches and non-starch polysaccharide sources affect the metabolism and disposition of the food carcinogen, 2-amino-3-methylimidazo[4,5-f]quinoline. Journal of Chromatography B. 802(1). 201–210. 6 indexed citations

Chung, Francisco, Brian D. Palmer, George W. Muller, et al.. (2003). Effect of 3-Fluorothalidomide and 3-Methylthalidomide Enantiomers on Tumor Necrosis Factor Production and Antitumor Responses to the Antivascular Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA). Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 14(2). 75–82. 13 indexed citations

Ching, L‐M, et al.. (2002). The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice. British Journal of Cancer. 87(4). 465–470. 60 indexed citations

Mitchell, S. C., P. Kestell, Glyn B. Steventon, & R. H. Waring. (2002). Fate of the anthelmintic, phenothiazine, in man. Xenobiotica. 32(9). 771–782. 4 indexed citations

Tingle, Malcolm D., et al.. (2002). Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acidin vitro: implications for prediction of metabolic interactionsin vivo. Xenobiotica. 32(2). 87–107. 18 indexed citations

10.

Zhou, Shu‐Feng, James W. Paxton, Malcolm D. Tingle, & P. Kestell. (2001). Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 757(2). 343–348. 8 indexed citations

11.

Paxton, James W., Malcolm D. Tingle, P. Kestell, et al.. (2001). Identification and reactivity of the major metabolite (ß-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica. 31(5). 277–293. 24 indexed citations

12.

Kestell, P., et al.. (2001). Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemotherapy and Pharmacology. 47(6). 491–497. 17 indexed citations

13.

Zhou, Shufeng, James W. Paxton, Malcolm D. Tingle, & P. Kestell. (2001). Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. Journal of Chromatography B Biomedical Sciences and Applications. 757(2). 359–363. 6 indexed citations

14.

Miners, John O., Luísa M.P. Valente, K.J. Lillywhite, et al.. (1997). Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.. PubMed. 57(2). 284–9. 58 indexed citations

15.

Kestell, P., Gordon W. Rewcastle, & Bruce C. Baguley. (1994). Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: Identification of metabolites and routes of elimination. Xenobiotica. 24(7). 635–647. 3 indexed citations

16.

Kestell, P., Mark J. McKeage, & Bruce C. Baguley. (1991). Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 564(1). 315–321. 5 indexed citations

17.

Kestell, P., James W. Paxton, P C Evans, et al.. (1990). Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice.. PubMed. 50(3). 503–8. 26 indexed citations

18.

Kestell, P., et al.. (1988). THIOLYTIC CLEAVAGE AND BINDING OF THE ANTITUMOUR AGENT CI-921 IN BLOOD. Drug metabolism and drug interactions. 6(3-4). 327–336. 4 indexed citations

19.

Kestell, P., et al.. (1987). An investigation of the relationship between the hepatotoxicity and the metabolism of N-alkylformamides.. Journal of Pharmacology and Experimental Therapeutics. 240(1). 265–270. 32 indexed citations

20.

Threadgill, Michael D., Donald B. Axworthy, Thomas A. Baillie, et al.. (1987). Metabolism of N-methylformamide in mice: primary kinetic deuterium isotope effect and identification of S-(N-methylcarbamoyl)glutathione as a metabolite.. Journal of Pharmacology and Experimental Therapeutics. 242(1). 312–319. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact